- Home
- AUID vs IGC Comparison
AUID vs IGC Comparison
Compare AUID & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUID | IGC |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 25.0M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AUID | IGC |
|---|---|---|
| Price | $1.32 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 257.5K | ★ 276.8K |
| Earning Date | 05-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | $886,485.00 | ★ $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 365.86 | N/A |
| 52 Week Low | $0.84 | $0.24 |
| 52 Week High | $9.44 | $0.50 |
Technical Indicators
Market Signals| Indicator | AUID | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 42.05 |
| Support Level | $1.19 | N/A |
| Resistance Level | $1.38 | $0.31 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 2.72 | 20.00 |
Price Performance
Historical ComparisonAbout AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.